Generation of Soluble NKG2D Ligands: Proteolytic Cleavage, Exosome Secretion and Functional Implications

Scandinavian Journal of Immunology

Volumn 78, Issue 2, 2013, Pages 120-129

  Chitadze, G ^a   Bhat, J ^a   Lettau, M ^a   Janssen, O ^a   Kabelitz, D ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NATURAL KILLER CELL RECEPTOR NKG2D;

EXOSOME; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSURVEILLANCE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; T LYMPHOCYTE; TUMOR CELL;

EXOSOMES; GENE EXPRESSION REGULATION, NEOPLASTIC; GPI-LINKED PROTEINS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOLOGIC SURVEILLANCE; KILLER CELLS, NATURAL; LIGANDS; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PROTEOLYSIS; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; TYPE C PHOSPHOLIPASES;

EID: 84880683894     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12072     Document Type: Review

References (105)

1. Campbell KS, Purdy AK. Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology 2011;132:315-25.
2. Hudspeth K, Silva-Santos B, Mavilio D. Natural cytotoxicity receptors: broader expression patterns and functions in innate and adaptive immune cells. Front Immunol 2013;4:69. doi: 10.3389/fimmu.2013.00069.
3. Campbell KS, Yusa S, Kikuchi-Maki A, Catina TL. NKp44 triggers NK cell activation through DAP12 association that is not influenced by a putative cytoplasmic inhibitory sequence. J Immunol 2004;172:899-906.
4. Vogler I, Steinle A. Vis-à-vis in the NKC: genetically linked natural killer cell receptor/ligand pairs in the natural killer gene complex (NKC). J Innate Immun 2011;3:227-35.
5. Zafirova B, Wensveen FM, Gulin M, Polić B. Regulation of immune cell function and differentiation by the NKG2D receptor. Cell Mol Life Sci 2011;68:3519-29.
6. Bryceson YT, March ME, Ljunggren HG, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 2006;107:159-66.
7. Bryceson YT, Long EO. Line of attack: NK cell specificity and integration of signals. Curr Opin Immunol 2008;20:344-52.
8. Bryceson YT, Ljunggren HG, Long EO. Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors. Blood 2009;114:2657-66.
9. Vivier E, Raulet DH, Moretta A et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011;331:44-9.
10. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003;3:781-90.
11. + T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset diabetes. J Exp Med 2009;206:793-805.
12. Wu J, Song Y, Bakker AB et al. An activating immuno-receptor complex formed by NKG2D and DAP10. Science 1999;285:730-2.
13. Billadeau DD, Upshaw JL, Schoon RA, Dick CJ, Leibson PJ. NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway. Nat Immunol 2003;4:557-64.
14. Upshaw JL, Arneson LN, Schoon RA, Dick CJ, Billadeau DD, Leibson PJ. NKG2D-mediated signalling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells. Nat Immunol 2006;7:524-32.
15. Park YP, Choi SC, Kiesler P et al. Complex regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the γc cytokines and TGF-β1. Blood 2011;118:3019-27.
16. Hanaoka N, Jabri B, Dai Z et al. NKG2D initiates caspase-mediated CD3zeta degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease. J Immunol 2010;185:5732-42.
17. Bauer S, Groh V, Wu J et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999;285:727-9.
18. Das H, Groh V, Kuijl C et al. MICA engagement by human Vγ2Vδ2 T cells enhances their antigen-dependent effector function. Immunity 2001;15:83-93.
19. Kuylenstierna C, Björkström NK, Andersson SK et al. NKG2D performs two functions in invariant NKT cells: direct TCR-independent activation of NK-like cytolysis and co-stimulation of activation by CD1d. Eur J Immunol 2011;41:1913-23.
20. Rajasekaran K, Xiong V, Fong L, Gorski J, Malarkannan S. Functional dichotomy between NKG2D and CD28-mediated co-stimulation in human CD8+ T cells. PLoS ONE 2010;5:e12635.
21. Paidipally P, Periasamy S, Barnes PF et al. NKG2D-dependent IL-17 production by human T cells in response to an intracellular pathogen. J Immunol 2009;183:1940-5.
22. Pariente B, Mocan I, Camus M et al. Activation of the receptor NKG2D leads to production of Th17 cytokines in CD4+ T cells of patients with Crohn's disease. Gastroenterology 2011;141:217-26.
23. Guerra N, Tan YX, Joncker NT et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008;28:571-80.
24. López-Soto A, Huergo-Zapico L, Galván JA et al. Epithelial-mesenchymal transition induces an antitumor immune response mediated by NKG2D receptor. J Immunol 2013;190:4408-19.
25. Benitez AC, Dai Z, Mann HH et al. Expression, signaling proficiency, and stimulatory function of the NKG2D lymphocyte receptor in human cancer cells. Proc Natl Acad Sci USA 2011;108:4081-6.
26. Fernández-Messina L, Reyburn HT, Valés-Gómez M. Human NKG2D-ligands: cell biology strategies to ensure immune recognition. Front Immunol 2012;3:299. doi: 10.3389/fimmu.2012.00299.
27. Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 2013;31:413-41.
28. Fernández-Messina L, Ashiru O, Agüera-González S, Reyburn HT, Valés-Gómez M. The human NKG2D ligand ULBP2 can be expressed at the cell surface with or without a GPI anchor and both forms can activate NK cells. J Cell Sci 2011;124:321-7.
29. Eagle RA, Jafferji I, Barrow AD. Beyond stressed self: evidence for NKG2D ligand expression on healthy cells. Curr Immunol Rev 2009;5:22-34.
30. Kloss M, Decker P, Baltz KM et al. Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA. J Immunol 2008;181:6711-9.
31. Schrama D, Terheyden P, Otto K et al. Expression of the NKG2D ligand UL16 binding protein-1 (ULBP-1) on dendritic cells. Eur J Immunol 2006;36:65-72.
32. Ebihara T, Masuda H, Akazawa T et al. Induction of NKG2D ligands on human dendritic cells by TLR ligand stimulation and RNA virus infection. Int Immunol 2007;19:1145-55.
33. Cerboni C, Zingoni A, Cippitelli M, Piccoli M, Frati L, Santoni A. Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK- cell lysis. Blood 2007;110:606-15.
34. Poggi A, Catellani S, Garuti A, Pierri I, Gobbi M, Zocchi MR. Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. Leukemia 2009;23:641-8.
35. Yamanegi K, Yamane J, Kobayashi K et al. Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity. Oncol Rep 2010;24:1621-7.
36. Wu X, Tao Y, Hou J, Meng X, Shi J. Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma. Neoplasia 2012;14:1178-89.
37. Jensen H, Hagemann-Jensen M, Lauridsen F, Skov S. Regulation of NKG2D-ligand cell surface expression by intracellular calcium after HDAC-inhibitor treatment. Mol Immunol 2013;53:255-64.
38. Rohner A, Langenkamp U, Siegler U, Kalberer CP, Wodnar-Filipowicz A. Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis. Leuk Res 2007;31:1393-402.
39. Tang KF, He CX, Zeng GL et al. Induction of MHC class I-related chain B (MICB) by 5-aza-2′-deoxycytidine. Biochem Biophys Res Commun 2008;370:578-83.
40. Song H, Kim KE, Hur D et al. IL-18 enhances ULBP2 expression through the MAPK pathway in leukemia cells. Immunol Lett 2008;120:103-7.
41. Okita R, Mougiakakos D, Ando T et al. HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines. J Immunol 2012;188:2136-45.
42. Hansen CH, Holm TL, Krych L et al. Gut microbiota regulates NKG2D ligand expression on intestinal epithelial cells. Eur J Immunol 2013;43:447-57.
43. Tsukerman P, Stern-Ginossar N, Gur C et al. MiR-10b downregulates the stress-induced cell surface molecule MICB, a critical ligand for cancer cell recognition by natural killer cells. Cancer Res 2012;72:5463-72.
44. Tsukerman P, Enk J, Mandelboim O. Metastamir-mediated immune evasion: miR-10b downregulates the stress-induced molecule MICB, hence avoid recognition by NKG2D receptor. Oncoimmunology 2013;2:e22245.
45. Heinemann A, Zhao F, Pechlivanis S et al. Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D. Cancer Res 2012;72:460-71.
46. Yadav D, Ngolab J, Lim RS, Krishnamurthy S, Bui JD. Cutting edge: down-regulation of MHC class I-related chain A on tumor cells by IFN-γ-induced microRNA. J Immunol 2009;182:39-43.
47. Eisele G, Wischhusen J, Mittelbronn M et al. TGF-β and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain 2006;129:2416-25.
48. Yamada N, Yamanegi K, Ohyama H et al. Hypoxia downregulates the expression of cell surface MICA without increasing soluble MICA in osteosarcoma cells in a HIF-1α-dependent manner. Int J Oncol 2012;41:2005-12.
49. Wu J, Chalupny NJ, Manley TJ, Riddell SR, Cosman D, Spies T. Intracellular retention of the MHC class I-related chain B ligand of NKG2D by the human cytomegalovirus UL16 glycoprotein. J Immunol 2003;170:4196-200.
50. Ashiru O, Bennett NJ, Boyle LH, Thomas M, Trowsdale J, Wills MR. NKG2D ligand MICA is retained in the cis-Golgi apparatus by human cytomegalovirus protein UL142. J Virol 2009;83:12345-54.
51. Bennett NJ, Ashiru O, Morgan FJ et al. Intracellular sequestration of the NKG2D ligand ULBP3 by human cytomegalovirus. J Immunol 2010;185:1093-102.
52. Jensen H, Andresen L, Nielsen J, Christensen JP, Skov S. Vesicular stomatitis virus infection promotes immune evasion by preventing NKG2D-ligand surface expression. PLoS ONE 2011;6:e23023.
53. Chen Z, Chen L, Baker K et al. CEACAM1 dampens antitumor immunity by down-regulating NKG2D ligand expression on tumor cells. J Exp Med 2011;208:2633-40.
54. Agüera-González S, Boutet P, Reyburn HT, Valés-Gómez M. Brief residence at the plasma membrane of the MHC class I-related chain B is due to clathrin-mediated cholesterol-dependent endocytosis and shedding. J Immunol 2009;182:4800-8.
55. Pende D, Rivera P, Marcenaro S et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 2002;62:6178-86.
56. Vetter CS, Groh V, thor Straten P, Spies T, Bröcker EB, Becker JC. Expression of stress-induced MHC class I related chain molecules on human melanoma. J Invest Dermatol 2002;118:600-5.
57. Wrobel P, Shojaei H, Schittek B et al. Lysis of a broad range of epithelial tumour cells by human γδ T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition. Scand J Immunol 2007;66:320-8.
58. Li K, Mandai M, Hamanishi J et al. Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol Immunother 2009;58:641-52.
59. McGilvray RW, Eagle RA, Watson NF et al. NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin Cancer Res 2009;15:6993-7002.
60. Hilpert J, Grosse-Hovest L, Grünebach F et al. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J Immunol 2012;189:1360-71.
61. Rincon-Orozco B, Kunzmann V, Wrobel P, Kabelitz D, Steinle A, Herrmann T. Activation of Vγ9Vδ2 T cells by NKG2D. J Immunol 2005;175:2144-51.
62. Salih HR, Rammensee HG, Steinle A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 2002;169:4098-102.
63. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002;419:734-8.
64. Salih HR, Goehlsdorf D, Steinle A. Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients. Hum Immunol 2006;67:188-95.
65. Boutet P, Aguera-González S, Atkinson S et al. Cutting edge: the metalloproteinase ADAM17/TNF-α-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein. J Immunol 2009;182:49-53.
66. Song H, Kim J, Cosman D, Choi I. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression. Cell Immunol 2006;239:22-30.
67. Waldhauer I, Steinle A. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res 2006;66:2520-6.
68. Fernández-Messina L, Ashiru O, Boutet P et al. Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)-anchored NKG2D ligands. J Biol Chem 2010;285:8543-51.
69. Cao W, Xi X, Hao Z et al. RAET1E2, a soluble isoform of the UL16-binding protein RAET1E produced by tumor cells, inhibits NKG2D-mediated NK cytotoxicity. J Biol Chem 2007;282:18922-8.
70. Bacon L, Eagle RA, Meyer M, Easom N, Young NT, Trowsdale J. Two human ULBP/RAET1 molecules with transmembrane regions are ligands for NKG2D. J Immunol 2004;173:1078-84.
71. Hedlund M, Nagaeva O, Kargl D, Baranov V, Mincheva-Nilsson L. Thermal- and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma T and B cells. PLoS ONE 2011;6:e16899.
72. Sun D, Wang X, Zhang H, Deng L, Zhang Y. MMP9 mediates MICA shedding in human osteosarcomas. Cell Biol Int 2011;35:569-74.
73. Liu G, Atteridge CL, Wang X, Lundgren AD, Wu JD. The membrane type matrix metalloproteinase MMP14 mediates constitutive shedding of MHC class I chain-related molecule A independent of A disintegrin and metalloproteinases. J Immunol 2010;184:3346-50.
74. Reiss K, Saftig P. The "a disintegrin and metalloprotease" (ADAM) family of sheddases: physiological and cellular functions. Semin Cell Dev Biol 2009;20:126-37.
75. Blobel CP. ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol 2005;6:32-43.
76. Weinlich R, Brunner T, Amarante-Mendes GP. Control of death receptor ligand activity by posttranslational modifications. Cell Mol Life Sci 2010;67:1631-42.
77. Murphy G. The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer 2008;8:929-41.
78. Claesson-Welsh L. ADAM-mediated shedding, a new flavor in angiogenesis regulation. Arterioscler Thromb Vasc Biol 2010;30:2087-8.
79. Witters L, Scherle P, Friedman S et al. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. Cancer Res 2008;68:7083-9.
80. Zhou BB, Peyton M, He B et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 2006;10:39-50.
81. Newton RC, Bradley EC, Levy RS et al. Clinical benefit of INCB7839, a potent and selective ADAM inhibitor, in combination with trastuzumab in patients with metastatic HER2+ breast cancer. J Clin Oncol 2010;28:15s. (abstract 3025).
82. Duffy MJ, Mullooly M, O'Donovan N et al. The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer? Clin Proteomics 2011;8:9.
83. Kohga K, Takehara T, Tatsumi T et al. Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9. Hepatology 2010;51:1264-73.
84. Waldhauer I, Goehlsdorf D, Gieseke F et al. Tumor-associated MICA is shed by ADAM proteases. Cancer Res 2008;68:6368-76.
85. Kaiser BK, Yim D, Chow IT et al. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature 2007;447:482-6.
86. Agüera-González S, Gross CC, Fernández-Messina L et al. Palmitoylation of MICA, a ligand for NKG2D, mediates its recruitment to membrane microdomains and promotes its shedding. Eur J Immunol 2011;41:3667-76.
87. Chitadze G, Lettau M, Bhat J et al. Shedding of endogenous MHC class I-related chain molecules A and B (MICA and MICB) from different human tumor entities: Heterogeneous involvement of the a disintegrin and metalloproteases 10 and 17 (ADAM10 and ADAM17). Int J Cancer 2013. doi: 10.1002/ijc.28174. [Epub ahead of print].
88. Gooz M. ADAM-17: the enzyme that does it all. Crit Rev Biochem Mol Biol 2010;45:146-69.
89. Ashiru O, Boutet P, Fernandez-Messina L et al. Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. Cancer Res 2010;70:481-9.
90. Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z. Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol 2008;180:7249-58.
91. Viaud S, Terme M, Flament C et al. Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Rα. PLoS ONE 2009;4:e4942.
92. Whiteside TL. Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem Soc Trans 2013;41:245-51.
93. Huang B, Sikorski R, Sampath P, Thorne SH. Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer. J Immunother 2011;34:289-96.
94. Kohga K, Tatsumi T, Tsunematsu H et al. Interleukin-1β enhances the production of soluble MICA in human hepatocellular carcinoma. Cancer Immunol Immunother 2012;61:1425-32.
95. Hedlund M, Stenqvist AC, Nagaeva O et al. Human placenta expresses and secretes NKG2D ligands via exosomes that down-modulate the cognate receptor expression: evidence for immunosuppressive function. J Immunol 2009;183:340-51.
96. Salih HR, Holdenrieder S, Steinle A. Soluble NKG2D ligands: prevalence, release, and functional impact. Front Biosci 2008;13:3448-56.
97. Märten A, von Lilienfeld-Toal M, Büchler MW, Schmidt J. Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing γδ T cell cytotoxicity. Int J Cancer 2006;119:2359-65.
98. Chang YT, Wu CC, Shyr YM et al. Secretome-based identification of ULBP2 as a novel serum marker for pancreatic cancer detection. PLoS ONE 2011;6:e20029.
99. Kohga K, Takehara T, Tatsumi T et al. Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma. Cancer Res 2009;69:8050-7.
100. Yamaguchi K, Chikumi H, Shimizu A et al. Diagnostic and prognostic impact of serum-soluble UL16-binding protein 2 in lung cancer patients. Cancer Sci 2012;103:1405-13.
101. Paschen A, Sucker A, Hill B et al. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res 2009;15:5208-15.
102. Nückel H, Switala M, Sellmann L et al. The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia. Leukemia 2010;24:1152-9.
103. + NKT-like cell cytotoxicity in cancer patients. Immunol Lett 2008;120:65-71.
104. Yamanegi K, Yamane J, Kobayashi K et al. Downregulation of matrix metalloproteinase-9 mRNA by valproic acid plays a role in inhibiting the shedding of MHC class I-related molecules A and B on the surface of human osteosarcoma cells. Oncol Rep 2012;28:1585-90.
105. Eagle RA, Flack G, Warford A et al. Cellular expression, trafficking, and function of two isoforms of human ULBP5/RAET1G. PLoS ONE 2009;4:e4503.